We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Blood-Based Biomarker Predicts Onset of Symptomatic Alzheimer’s Disease

By LabMedica International staff writers
Posted on 16 Sep 2021
Print article
Image: The EASY-nLC 1000 HPLC system is s a fully integrated, split-free, nanoflow liquid chromatograph optimized for separating biomolecules such as proteins and peptides (Photo courtesy of Thermo Fisher Scientific)
Image: The EASY-nLC 1000 HPLC system is s a fully integrated, split-free, nanoflow liquid chromatograph optimized for separating biomolecules such as proteins and peptides (Photo courtesy of Thermo Fisher Scientific)
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, starting with a preclinical phase of normal cognition lasting approximately two decades. The formal diagnosis of AD dementia, relies on neuropsychological tests further confirmed by brain imaging and cerebrospinal fluid (CSF) sampling.

The pathogenic features of AD that have an onset in the preclinical phase may allow identification of such early blood-based biomarkers. By eliciting compensatory responses, these early pathogenic changes were found to initially prevent the increase in reactive oxygen and nitrogen species (ROS/RNS) through activation of antioxidant mechanisms.

Scientists at the University of Brescia (Brescia, Italy) and their colleagues collected blood samples from 482 subjects aged between 60 and 85 years who did not present specific comorbidities (uncontrolled diabetes, vascular disease, severe depression, or psychiatric illnesses) and were included in a retrospective study collecting a total of 515 blood samples from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study by applying a consecutive sampling approach.

The team performed immunoprecipitation (IP) followed by liquid chromatography (LC) tandem mass spectrometry (MS/MS) and protein sequencing in plasma samples from the AIBL study identified the clinically relevant AZ 284 peptide (AlzoSure Predict test, Diadem, Brescia, Italy), representing a measure of the U-p53 conformational variant (U-p53AZ). Based on U-p53AZ quantification via IP/LC electrospray ionization-coupled MS/MS (Thermo Scientific EASY-nLC 1000 HPLC system, coupled to a Thermo Fisher Scientific EASYSpray source, Waltham MA, USA), supported by an analytical nanoflow column system. The predictive performance of U-p53AZ was assessed and compared with amyloid load as measured by amyloid β-positron emission tomography (Aβ-PET). Its predictive performance was determined at 36, 54, 72 and 90 months.

The investigators reported that U-p53AZ was able to identify individuals with AD dementia with an area under the receiver operating characteristic curve (AUC) of 99%. U-p53AZ outperformed the conventional Aβ-PET measures in predicting the onset of AD dementia both from preclinical (AUC=98%) and prodromal stages (AUC=89%), even 90 months prior to onset (AUC=99%). Additionally, the estimated predictive performance of U-p53AZ was superior (AUC ≥98%) to other risk factors (i.e., gender, Aβ-PET and APOE ε4 allele status) in identifying individuals at high risk for progression to AD.

The authors concluded that their findings support use of U-p53AZ as blood-based biomarker predicting if individuals, at both asymptomatic and MCI stages, would progress to AD at least six years prior to the onset of clinical AD dementia. The study was published on August 25, 2021 in the journal medRxiv.

Related Links:
University of Brescia
Diadem
Thermo Fisher Scientific


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.